InVivo Therapeutics Announces Sixth Patient Conversion in The INSPIRE Study of the Neuro-Spinal Scaffold™

Autor:	InVivo Therapeutics Holdings Corp.
Zdroj:	Business Wire (English). 01/24/2017.
Abstrakt:	InVivo Therapeutics Holdings Corp. (NVIV) today announced that the patient enrolled in December in the INSPIRE study of the Neuro-Spinal Scaffold has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury in the time between discharge and the one-month evaluation. This is the sixth out of the eleven patients (54.5% conversion rate) in follow-up to have had an AIS grade improvement. Two patients who have not yet converted are early in follow-up, with conversion possible before the six-month endpoint. The INSPIRE conversion rate is considerably higher than rates observed in a range of SCI natural history databases. [ABSTRACT FROM PUBLISHER]
Databáze:	Regional Business News
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.